ホーム > 松阪諭/ Matsusaka, Satoshi

松阪諭

ALUMNI 2025年11月現在、筑波大学が主たる所属機関ではありません

Matsusaka, Satoshi

医学医療系 , 教授
Faculty of Medicine , Professor

オープンアクセス版の論文は「つくばリポジトリ」で読むことができます。

41. Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach Yan Ning; Diana L. Hanna; Wu Zhang; Angela Mendez (+9 著者) Heinz-Josef Lenz
MOLECULAR CANCER THERAPEUTICS 14: 2401 (2015) Semantic Scholar
42. Variations in genes involved in dormancy associated with outcome in patients with resected colorectal liver metastases S. Stremitzer; W. Zhang; D. Yang; Y. Ning (+11 著者) H. -J. Lenz
ANNALS OF ONCOLOGY 26: 1728 (2015) Semantic Scholar
43. A multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (SHOGUN trial) Satoshi Matsusaka; Soichiro Ishihara; Keisaku Kondo; Hisanaga Horie (+16 著者) Toshiaki Watanabe
RADIOTHERAPY AND ONCOLOGY 116: 209 (2015) Semantic Scholar
44. Genetic variations in angiopoietin and pericyte pathways and clinical outcome in patients with resected colorectal liver metastases Stefan Stremitzer; Wu Zhang; Dongyun Yang; Yan Ning (+9 著者) Heinz-Josef Lenz
CANCER 121: 1898 (2015) Semantic Scholar
45. Association of variants in genes encoding for macrophage-related functions with clinical outcome in patients with locoregional gastric cancer Y. Sunakawa; S. Stremitzer; S. Cao; W. Zhang (+13 著者) H. -J. Lenz
ANNALS OF ONCOLOGY 26: 332 (2015) Semantic Scholar
46. A novel approach to detect KRAS/BRAF mutation for colon cancer: Highly sensitive simultaneous detection of mutations and simple pre-treatment without DNA extraction S, Suzuki; S, Matsusaka; M, Hirai; H, Shibata (+2 著者) K, Hatake
Int J Oncol 47: 97 (2015) Semantic Scholar
47. Perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01) Mitsukuni Suenaga; Yoshiya Fujimoto; Satoshi Matsusaka; Eiji Shinozaki (+6 著者) Toshiharu Yamaguchi
ONCOTARGETS AND THERAPY 8: 1111 (2015) Semantic Scholar
48. Cetuximab could be more effective without prior bevacizumab treatment in metastatic colorectal cancer patients Yasuyoshi Sato; Satoshi Matsusaka; Mitsukuni Suenaga; Eiji ShinozakiNobuyuki Mizunuma
ONCOTARGETS AND THERAPY 8: 3329 (2015) Semantic Scholar
49. Angiotensin II type-1 receptor blockers enhance the effects of bevacizumab-based chemotherapy in metastatic colorectal cancer patients. Matsusaka, Satoshi; S, Matsusaka; T, Wakatsuki; M, Suenaga (+1 著者) N, Mizunuma
Mol Clin Oncol. 3: 1295 (2015)
50. Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy? H, Osumi; E, Shinozaki; M, Suenaga; Y, Kumekawa (+5 著者) N, Mizunuma
BMC Cancer 15: 760 (2015) Semantic Scholar
51. A phase I dose escalation study of oxaliplatin plus oral S-1 and pelvic radiation in patients with locally advanced rectal cancer (SHOGUN trial). Ishihara S; S, Matsusaka; K, Kondo; H, Horie (+17 著者) Watanabe
Radiat Oncol 10: 24 (2015) Semantic Scholar
52. Anticoagulant therapy for venous thromboembolism detected by Doppler ultrasound in patients with metastatic colorectal cancer receiving bevacizumab Mitsukuni Suenaga; Nobuyuki Mizunuma; Eiji Shinozaki; Satoshi Matsusaka (+3 著者) Toshiharu Yamaguchi
ONCOTARGETS AND THERAPY 8: 243 (2015) Semantic Scholar
53. Variations in genes involved in immune response checkpoints and association with outcomes in patients with resected colorectal liver metastases. Pharmacogenomics J S, Stremitzer; Y, Sunakawa; W, Zhang; D, Yang (+9 著者) HJ., Lenz
Pharmacogenomics J 15: 521 (2015) Semantic Scholar
54. Genetic variants within obesity-related genes are associated with tumor recurrence in patients with stages II/III colon cancer Ana Sebio; Armin Gerger; Satoshi Matsusaka; Dongyun Yang (+8 著者) Heinz-Josef Lenz
PHARMACOGENETICS AND GENOMICS 25: 30 (2015) Semantic Scholar
55. Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival. H, Osumi; E, Shinozaki; M, Osako; Y, Kawazoe (+11 著者) N, Mizunuma
Mol Clin Oncol. 3: 1053 (2015)
56. Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab Hiroki Osumi; Satoshi Matsusaka; Mitsukuni Suenaga; Eiji ShinozakiNobuyuki Mizunuma
ONCOTARGETS AND THERAPY 8: 2005 (2015) Semantic Scholar
57. Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study Mitsukuni Suenaga; Nobuyuki Mizunuma; Satoshi Matsusaka; Eiji Shinozaki (+2 著者) Toshiharu Yamaguchi
DRUG DESIGN DEVELOPMENT AND THERAPY 9: 3099 (2015) Semantic Scholar
58. A novel detection strategy for living circulating tumor cells using 5-aminolevulinic acid Satoshi Matsusaka; Masahiro Kozuka; Hidenori Takagi; Hiroshi Ito (+2 著者) Kiyohiko Hatake
CANCER LETTERS 355: 113 (2014) Semantic Scholar
59. Retrospective analysis on the efficacy of bevacizumab with FOLFOX as a first-line treatment in Japanese patients with metastatic colorectal cancer Mitsukuni Suenaga; Nobuyuki Mizunuma; Satoshi Matsusaka; Eiji Shinozaki (+1 著者) Toshiharu Yamaguchi
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 10: 322 (2014) Semantic Scholar
60. Single nucleotide polymorphisms in AREG and EREG are prognostic biomarkers in locally advanced gastric cancer patients after surgery with curative intent Takeru Wakatsuki; Sebastian Stintzing; Wu Zhang; Dongyun Yang (+11 著者) Heinz-Josef Lenz
PHARMACOGENETICS AND GENOMICS 24: 539 (2014) Semantic Scholar

« 1 2 3 4 »

1. Role of enterocyte-specific gene polymorphisms in response to adjuvant treatment for stage III colorectal cancer. Matsusaka, Satoshi
Pharmacogenet Genomics. 2021年1月
2. A novel system to detect circulating tumor cells using two different size-selective microfilters. 松阪, 諭
Anticancer Res. 2020年10月
3. Polymorphisms within immune regulatory pathways predict cetuximab efficacy and survival in metastatic colorectal cancer patients. 松阪, 諭
2020年10月
4. A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer. 松阪, 諭
PloS One. 2020年9月
5. Raman image-activated cell sorting. Matsusaka, Satoshi
Nat Commun. 2020年7月
6. Sequentially addressable dielectrophoretic array for high-throughput sorting of large-volume bioliogical compartments. 松阪, 諭
Sci Adv. 2020年5月
7. Virtual-freezing fluorescence imaging flow cytometry Matsusaka, Satoshi
Nat Commun. 2020年3月
8. Epidermal growth factor receptor mRNA expression: A potential molecular escape mechanism from regorafenib. Matsusaka, Satoshi
Cancer Sci. 2020年2月
9. Label-free chemical imaging flow cytometry by high-speed multicolor stimulated Raman scattering. 松阪, 諭
Proc Natl Acad Sci U S A. 2019年8月
10. A practical guide to intelligent image-activated cell sorting Matsusaka, Satoshi
2019年8月
11. Long-term results of a multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (JACCRO CC-04: SHOGUN Trial). 松阪, 諭
Radiother Oncol. 2019年5月
12. A polymorphism within the vitamin D transporter gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab or FOLFIRI/cetuximab. 松阪, 諭
2018年2月
13. 医学のあゆみ松阪,諭 (担当:分担執筆, 範囲:リキッドバイオプシー-がんにおける臨床応用と将来展望)
医歯薬出版 2018年
14. 大腸癌FRONTIER 松阪, 諭; 畠精彦 (担当:分担執筆, 範囲:微量癌細胞検出の臨床的意義〜腫瘍内科医の立場から)
2012年
15. Frontiers in Gastroenterology 松阪,諭 (担当:分担執筆, 範囲:大腸癌補助化学療法におけるオキサリプラチン使用の是非肯定派)
2012年
16. 最新医学松阪,諭 (担当:分担執筆, 範囲:末梢循環血管内皮細胞(CEC)と末梢循環血管内皮前駆細胞(CEP))
2011年
17. 細胞工学別冊松阪, 諭; 三嶋雄二; 畠精彦 (担当:分担執筆, 範囲:CTCによるトランスレーショナルリサーチ)
2010年
18. 医学のあゆみ松阪,諭 (担当:分担執筆, 範囲:抗体医薬に対するバイオマーカー-末梢循環癌細胞(CTC), 末梢循環血管内皮細胞(CEC), 末梢循環血管内皮前駆細胞(CEP))
医歯薬出版 2009年
19. 医学のあゆみ松阪,諭 (担当:分担執筆, 範囲:抗体医薬に対するバイオマーカー-末梢循環癌細胞(CTC), 末梢循環血管内皮細胞(CEC), 末梢循環血管内皮前駆細胞(CEP))
医歯薬出版 2009年
20. Gan To Kagaku Ryoho 松阪,諭 (担当:分担執筆, 範囲:Biomarker for chemotherapy in patients with colorectal cancer)
2009年

1. Label-free three dimensional optical coherence tomography (OCT-) based imaging method for drug response evaluation of human derived tumor spheroids Abd El-Sadek; Ibrahim; Miyazawa, Arata; Mori, Tomoko; Shen, Larina Tzu-Wei; Makita, Shuichi; Mukherjee, Pradipta; Matsusaka, Satoshi; Yasuno, Yoshiaki
Photonics West 2022年2月22日
2. Three dimensional tumor spheroid drug response evaluation using OCT based tissue viability evaluation method Abd El-Sadek; Ibrahim; Miyazawa, Arata; Mori, Tomoko; Shen, Larina Tzu-Wei; Makita, Shuichi; Mukherjee, Pradipta; Matsusaka, Satoshi; Yasuno, Yoshiaki
Photonics West 2022年2月22日
3. Label-free three dimensional evaluation of tumor spheroid drug response using dynamics optical coherence tomography Abd El-Sadek; Ibrahim; Miyazawa, Arata; Shen, Larina Tzu-Wei; Mori, Tomoko; Makita, Shuichi; Mukherjee, Pradipta; Matsusaka, Satoshi; Yasuno, Yoshiaki
Optics and Photonics Japan 2021年
4. がん分子標的治療の基本講座セッション１９「CTC」松阪, 諭
第22回日本がん分子標的治療学会学術集会基調講演
5. Symposium 6: Biomarker CTC, and circulating DNA 松阪, 諭
Anti-Cancer Treatment
6. 「がん診断・治療におけるCTCの有用性と今後の展望」松阪,諭
化学とマイクロ・ナノシステム学会第37回研究会招待講演
7. ゲノム解析を目指したCTC診断装置の開発松阪, 諭
第4回Liquid Biopsy研究会シンポジウム「ゲノム医療の時代におけるリキッドバイオプシーの役割」

1. 2022-3302: 細胞外小胞低減システム
松阪, 諭
2. 2022-3302: 細胞外小胞低減システム
松阪, 諭
3. 2022-017529: 細胞培養容器
松阪, 諭

1,411 total views

この研究者の他の情報源

キーワードが似ている研究者

篠崎鉄哉 ALUMNI バイオマーカー, biomarker
德田慶太 ALUMNI biomarker, バイオマーカー
須藤勝美バイオマーカー, Biomarker
近藤匡 ALUMNI 大腸癌
坂東裕子バイオマーカー

この研究者の他の情報源

キーワードが似ている研究者

この研究者の情報を共有